LambdaVision to Study Light-Activated Proteins on NASA’s Upcoming Flight to International Space Station

Research allows Company to explore potential benefits of microgravity for development of its artificial retina, and lays the groundwork for future missions

FARMINGTON, Conn.--(BUSINESS WIRE)-- LambdaVision, an innovative biotech developing a treatment to help patients regain sight, will launch their artificial retina technology with engineering partner Space Tango on Northrop Grumman’s 14^th Commercial Resupply Services Mission for NASA (NG-14) to the International Space Station (ISS) U.S. National Laboratory. Scheduled to launch on September 30^th at 2:26 UTC (10:26 p.m. ET), NG-14 is the first of a series of NASA flights to the ISS in low-Earth orbit (LEO) focused on developing the on-orbit production of LambdaVision’s artificial retina. LambdaVision’s research on the ISS focuses on exploring the benefits of microgravity for producing its artificial retina, and expands on research being conducted on Earth and previous efforts on the ISS. Funding for this research effort was made possible by two awards from NASA that underscore the technology readiness and commercial potential of the product, while supporting NASA’s strategic plan to leverage microgravity for a broad range of biomedical and technology applications.

“As we continue to grow the low-Earth orbit economy, missions such as this lend great insight into the potential uses of microgravity,” said Space Tango Chief Executive Officer and Co-Founder Twyman Clements. “Space Tango is excited for our continued partnership with LambdaVision as we develop innovative production methods in space to support their novel approach to restoring meaningful vision to patients with advanced retinal degenerative diseases.”

The first study materials for this series of missions will launch from Wallops Island, Virginia on Northrop Grumman’s Antares rocket and Cygnus capsule and will remain inside the ISS National Laboratory for approximately three months. LambdaVision will utilize this mission to further study the light-activated protein, bacteriorhodopsin, in a microgravity environment. This work will allow LambdaVision to evaluate the effects of microgravity on protein function and stability, which is critical for the quality and performance of the artificial retina. Importantly, the outcomes of this experiment will provide a foundation for future ISS-based production trials. The company also continues to refine and evaluate the production process for the protein-based artificial retina in its laboratories on Earth.

“Partnering with NASA and Space Tango continues to be an important catalyst towards addressing the production requirements associated with our artificial retina technology. Their support and resources offer a unique environment that allows us to generate high-quality artificial retinas that have the potential to restore visual acuity for blind patients,” said Jordan Greco, PhD, chief scientific officer, LambdaVision. “While our focus at this time is fully on our ability to restore meaningful sight to patients with retinitis pigmentosa (RP) and age-related macular degeneration (AMD), we are continually bolstered by the great potential of LEO for broader implications across industries.”

Over the next three years, the LambdaVision-Space Tango partnership will serve to evaluate and improve on-orbit production processes, and to produce artificial retinas that will then be evaluated on Earth. Once validated, this process could also provide the foundation for products in a range of industries that could be manufactured in space with potential clinical benefit to patients on Earth. To enable this effort, earlier this year, LambdaVision received from NASA a Small Business Innovation Research (SBIR) Phase II award, worth $750,000 over two years. In addition, the company and its partner, Space Tango, have also received a $5M NASA Commercialization Award for this continued work on the ISS.

By using proteins similar to the visual pigment, rhodopsin, that is naturally found in our eyes, LambdaVision’s protein-based artificial retina naturally mimics the light-absorbing properties of human photoreceptors and is capable of activating the degenerative retinas of blind patients. The implantable technology is produced through a layer-by-layer manufacturing process that ensures the artificial retina is dense enough to absorb appropriate amounts of light.

Exploring production of the artificial retina for a rare disease before moving to diseases which affect a significantly larger portion of the population, such as AMD, provides several strategic advantages toward the creation of a new low-Earth orbit biomedical sector. These include more manageable production volumes required to supply clinical trials, and a stepwise transition to commercial production volumes and scale required for future applications reaching a larger patient population. Upon finalization of optimal production processes, and pre-clinical studies, LambdaVision intends to initiate clinical trials for the treatment of advanced RP.

About Space Tango

Space Tango’s mission is to manufacture health and technology products in space that create value and transformational solutions. As a leader in automated systems, Space Tango pursues pathways to on-orbit production with a diverse partner-base. Our vision is to inspire, innovate and create a better future for humanity by utilizing the environment of space. Since 2017 through a NASA Space Act Agreement, Space Tango provides facilities on the International Space Station to support iterative R&D and pilot manufacturing. Space Tango is headquartered in Lexington, Kentucky with offices in Texas, Florida, California, and Washington, D.C. For more information, visit www.spacetango.com.

About LambdaVision

LambdaVision is developing a protein-based artificial retina to restore meaningful vision for the millions of patients blinded by retinal degenerative diseases, including retinitis pigmentosa (RP) and age-related macular degeneration (AMD). The patent-protected artificial retina technology developed by LambdaVision uses photoactive proteins to naturally mimic the light-absorbing properties of human photoreceptor cells and activate neuroreceptors still present in degenerated retinas of blind patients. Founded as part of the UConn Technology Incubator Program, LambdaVision along with its research partners, have secured over $8.0 million to date in state and federal funding. To learn more, visit lambdavision.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200925005063/en/